Recently, full data from the Phase II IDeate-Lung01 study on the antibody-drug conjugate I-DXd in previously treated extensive-stage small-cell lung cancer (ES-SCLC) were publish...
With the rapid development of precision medicine, targeted drugs have become a key approach in cancer treatment. Unlike traditional chemotherapy, targeted therapy “hits” specific...